| Code | CSB-RA021334MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BYON-4228, targeting Signal Regulatory Protein Alpha (SIRPA, also known as CD172a). SIRPA is an inhibitory receptor expressed primarily on myeloid cells, including macrophages, dendritic cells, and neutrophils, where it plays a critical role in regulating innate immune responses. Upon binding to its ligand CD47, SIRPA transmits a "don't eat me" signal that inhibits phagocytosis, allowing cells to evade immune clearance. This mechanism is frequently exploited by cancer cells to escape immune surveillance, making the SIRPA-CD47 axis a significant target in immuno-oncology research. Dysregulation of SIRPA signaling has been implicated in various malignancies, autoimmune disorders, and inflammatory diseases.
BYON-4228 is a research-oriented antibody drug that targets SIRPA and is currently in the early stage of development. BYON-4228 is designed to have a high affinity for SIRPA on the surface of macrophages. By occupying SIRPA, it blocks the binding of CD47 to SIRPA, thereby reactivating the macrophages' ability to recognize and engulf tumor cells. This biosimilar antibody serves as a valuable research tool for investigating SIRPA biology, exploring innate immune checkpoint mechanisms, and studying therapeutic strategies aimed at disrupting CD47-SIRPA interactions in cancer and immune-related pathologies.
There are currently no reviews for this product.